Rork Jillian F, Margossian Steven P, Nambudiri Vinod E, Huang Jennifer T
*Dermatology Program, Harvard Medical School, Boston Children's Hospital †Department of Hematology/Oncology, Harvard Medical School, Boston Children's Hospital, Dana-Farber Cancer Institute ‡Harvard Combined Dermatology Residency Program, Department of Dermatology, Harvard Medical School, Boston, MA.
J Pediatr Hematol Oncol. 2014 Apr;36(3):224-7. doi: 10.1097/MPH.0b013e31828e5d96.
Although it is known that hematopoietic stem cell transplantation (HSCT) survivors are at risk of nonmelanoma skin cancer (NMSC), there is limited literature on the incidence of NMSC during childhood in this population. We present 4 HSCT patients ages 13 to 20 years diagnosed with NMSC in our clinic over a 1-year period. Each patient had multiple risk factors associated with NMSC including chronic graft-versus-host disease, prolonged immunosuppression, total-body irradiation, and voriconazole therapy. We conclude that the incidence of NMSC in children after HSCT may be underestimated and should be further investigated. Appropriate skin cancer screening, including annual skin examinations, are advised for pediatric patients with identifiable risk factors.
虽然已知造血干细胞移植（HSCT）幸存者有患非黑色素瘤皮肤癌（NMSC）的风险，但关于该人群儿童期NMSC发病率的文献有限。我们报告了在1年时间里在我们诊所诊断为NMSC的4例年龄在13至20岁的HSCT患者。每位患者都有多个与NMSC相关的风险因素，包括慢性移植物抗宿主病、长期免疫抑制、全身照射和伏立康唑治疗。我们得出结论，HSCT后儿童NMSC的发病率可能被低估，应进一步研究。建议对有可识别风险因素的儿科患者进行适当的皮肤癌筛查，包括每年的皮肤检查。
